Documented infections due to organisms producing inducible β-lactamases or Extended-Spectrum β-lactamases (ESBL) resistant to alternate agents.
Empiric Treatment of life-threatening infections where multi-drug resistant organisms suspected (i.e. severe sepsis, neutropenic patient with absolute neutrophil count < 0.5)
Therapy of P. aeruginosa infections where other agents cannot be used due to allergy or toxicity
Therapy of documented or suspected infections due to MRSA, Enterococcus spp., Stenotrophomonas maltophilia, Chlamydia spp. and Mycoplasma spp.
Treatment of infections due to organisms susceptible to less costly and/or narrower-spectrum agents
Therapy of serious, often nosocomial infections involving resistant gram negative organisms
Immediate and delayed-type allergy
Cytopenias, positive Coombs
Liver enzyme abnormalities
Carbapenems may cause rapid and profound decrease in valproic acid levels.
Increasing valproic acid dosage is often NOT sufficient to overcome this interaction.
Avoid this combination if at all possible.
Dilute in 100 mL D5W or NS and administer over 30 min
EH Prescribing Restrictions
None (Pharmacist review of therapy)
Community IV Formulary (Metro Region)
Antimicrobial class: Carbapenem
Pregnancy category: B
Average serum half life: 1 hour
Biliary penetration: Therapeutic
CSF penetration: Moderate
Lung penetration: Therapeutic
Urine penetration: Therapeutic